CollPlant Biotechnologies Earnings Call Transcripts
Fiscal Year 2026
-
A strategic acquisition introduces a disruptive all-optical computing platform targeting the $89B HPC market, with a performance-driven deal structure and strong customer validation, including Boeing. Commercialization is underway, with product launch targeted for 2028.
Fiscal Year 2024
-
Revenues declined sharply year-over-year due to a prior $10M AbbVie milestone, with a net loss of $16.6M in 2024. Proprietary programs in dermal fillers and breast implants advanced, and cash runway extends into Q2 2026.
-
Advanced preclinical breast implant studies showed strong tissue integration and safety, while revenues declined sharply year-over-year due to the absence of milestone payments. Cash reserves of $15.4 million are expected to fund operations through 2025, with new collaborations targeted for next year.
-
Q2 2024 revenue dropped sharply year-over-year due to a prior $10M AbbVie milestone, resulting in a net loss, while cash reserves remain strong. Progress continues in regenerative breast implants and dermal fillers, with new preclinical studies and expanded patent coverage.